bcj201642a.pdf (517.6 kB)
Obinutuzumab-induced coagulopathy in chronic lymphocytic leukaemia with trisomy 12.
journal contribution
posted on 2016-11-15, 15:52 authored by H. S. Walter, S. Jayne, P. Mensah, F. M. Miall, M. Lyttelton, M. J. Dyer[First paragraph] Obinutuzumab, an afucosylated, type 2 anti-CD20 antibody,
showed superior results to rituximab in a head-to-head comparison
in combination with chlorambucil in the first-line treatment of
chronic lymphocytic leukaemia (CLL) patients with comorbidities
in the CLL11 trial (NCT01010061).1 Enhanced activity of obinutuzumab
in this setting may reflect better binding to Fc receptors as
well as the direct activation of the lysosomal cell death pathway
mediated by type 2 CD20 antibodies
Funding
We thank the patient and her family for participating in this clinical trial and the GP28331 study site staff on the Hope Unit at the Leicester Royal Infirmary. We also thank Dr Gregory Vosganian and his colleagues at Genentech and Roche for their help and review of the case. Studies were supported by the Leicester Experimental Cancer Medicine Centre (C325/A15575 Cancer Research UK/UK Department of Health).
History
Citation
Blood Cancer Journal (2016) 6, e435;Author affiliation
/Organisation/COLLEGE OF MEDICINE, BIOLOGICAL SCIENCES AND PSYCHOLOGY/School of Medicine/Department of Cancer Studies and Molecular MedicineVersion
- VoR (Version of Record)
Published in
Blood Cancer Journal (2016) 6Publisher
Nature Publishing Groupissn
2044-5385eissn
2044-5385Available date
2016-11-15Publisher DOI
Publisher version
http://www.nature.com/bcj/journal/v6/n6/full/bcj201642a.htmlLanguage
enAdministrator link
Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC